This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Klein, L. W. Search for Related Content PubMed PubMed Citation Articles by Klein, L. W.

VIEWPOINT

Are Drug-Eluting Stents the Preferred Treatment for Multivessel Coronary Artery Disease?

Rush Medical College, Chicago, Illinois, and Clinical Cardiology Associates, Gottlieb Memorial Hospital, Melrose Park, Illinois

Manuscript received June 27, 2005; revised manuscript received August 1, 2005, accepted August 2, 2005.

^_* Reprint requests and correspondence: Dr. Lloyd W. Klein, Gottlieb Memorial Hospital, Professional Office Building Suite #314, 675 West North Avenue, Melrose Park, Illinois 60160. (Email: lloydklein{at}comcast.net).

Drug-eluting stents (DES) constitute a major breakthrough in restenosis prevention after initial percutaneous coronary intervention (PCI). Target lesion and vessel revascularization rates of <10% at six months follow-up represent a significant medical advance. Many cardiologists consider it reasonable to assume that PCI using DES ought to be considered equivalent, if not superior, to bypass surgery. The argument made is that in previous randomized clinical trials comparing PCI to coronary artery bypass grafting, restenosis was the determining factor favoring surgery, an event that clinical experience suggests is no longer as frequent. In the absence of a definitive clinical trial to support this view, how should the prudent, cutting edge cardiologist evaluate the data and manage their patients?

Abbreviations and Acronyms   ARTS = Arterial Revascularization Therapies Study   BMS = bare-metal stent   CABG = coronary artery bypass grafting   CAD = coronary artery disease   DES = drug-eluting stents   ERACI = Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease   PCI = percutaneous coronary intervention

This article has been cited by other articles:

				J. H. Yang, H.-C. Gwon, S. J. Cho, J. Y. Hahn, J.-H. Choi, S. H. Choi, Y. T. Lee, S. H. Lee, K. P. Hong, and J. E. Park Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease Ann. Thorac. Surg., January 1, 2008; 85(1): 65 - 70. [Abstract] [Full Text] [PDF]

				S. H Wong, S. Wan, and M. J Underwood Myocardial Revascularization: Surgery or Stenting? Asian Cardiovasc Thorac Ann, June 1, 2007; 15(3): 264 - 269. [Abstract] [Full Text] [PDF]

				T. P. Martens, M. Argenziano, and M. C. Oz New Technology for Surgical Coronary Revascularization Circulation, August 8, 2006; 114(6): 606 - 614. [Full Text] [PDF]

				R. A. Guyton Coronary Artery Bypass is Superior to Drug-Eluting Stents in Multivessel Coronary Artery Disease Ann. Thorac. Surg., June 1, 2006; 81(6): 1949 - 1957. [Abstract] [Full Text] [PDF]